What Happened?

Shares of medical technology company Teleflex (NYSE:TFX) fell 22.9% in the morning session after the company reported disappointing fourth-quarter results, with revenue missing expectations by a significant margin. On a constant currency basis, revenue increased 3.2%, but this still fell short of Wall Street's estimates. Weak demand in Interventional Urology wiped out gains in the Interventional and Surgical units. Looking ahead, the company's 2025 revenue guidance implies little to no growth, with management projecting revenue to be flat to slightly up. Overall, this was a weaker quarter, weighed down by sluggish growth, margin pressures, and a subdued outlook​.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Teleflex? Access our full analysis report here, it’s free.

What The Market Is Telling Us

Teleflex’s shares are not very volatile and have only had 4 moves greater than 5% over the last year. Moves this big are rare for Teleflex and indicate this news significantly impacted the market’s perception of the business.

Teleflex is down 22.8% since the beginning of the year, and at $138.26 per share, it is trading 44.1% below its 52-week high of $247.32 from September 2024. Investors who bought $1,000 worth of Teleflex’s shares 5 years ago would now be looking at an investment worth $410.13.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.